Research dossier
Clinical research on Saffron
8 trials reviewed across 4 indications.
Strongest evidence
Depression & low mood
Mechanism
Saffron's active constituents — crocin, crocetin, and safranal — appear to modulate serotonin (inhibiting reuptake), dopamine and norepinephrine, plus antioxidant and anti-inflammatory effects on the brain. The serotonergic action is the proposed antidepressant lever.
The strongest case for saffron. Placebo-controlled RCTs and a meta-analysis show a clear antidepressant effect in mild-to-moderate depression, and head-to-head trials found 30 mg/day comparable to low-dose fluoxetine or imipramine. A branded extract (affron) also improved subclinical low mood. The effect is genuine and consistent in direction.
Evidence is for mild-to-moderate depression and low mood, mostly from a few Iranian research groups in small short trials. Not a replacement for treatment of moderate-to-severe depression, and independent large-scale replication outside Iran is still limited.
Trials cited
Saffron and major depressive disorder (meta-analysis)
positive · Meta-analysis
Hausenblas et al., 2013, Journal of Integrative Medicinen=230Pooled 5 RCTs. Large effect size for saffron vs placebo (ES = 1.62, p<0.001) and a null difference vs antidepressants (ES = -0.15) — i.e. saffron performed similarly to standard antidepressants and clearly beat placebo. Mean trial quality (Jadad) was high.
All included trials were conducted by the same Iranian research group and were small and short. A large pooled effect size from a single research lineage is not the same as broad independent replication.
Saffron vs placebo for mild-to-moderate depression
positive · RCT
Akhondzadeh et al., 2005, Phytotherapy Researchn=4040 depressed outpatients: saffron 30 mg/day produced a significantly greater HAM-D reduction than placebo (p<0.001) over 6 weeks, with no meaningful difference in side effects. A clean placebo-controlled signal for the antidepressant effect.
Small (n=40), short (6 weeks), and from the Akhondzadeh group, which generated much of the early saffron-depression literature. Needs independent, non-Iranian replication at scale.
Saffron vs fluoxetine for mild-to-moderate depression
positive · RCT
Noorbala et al., 2005, Journal of Ethnopharmacologyn=40Head-to-head: saffron 30 mg/day was as effective as fluoxetine 20 mg/day over 6 weeks (no significant between-group difference, p=0.71), with comparable side-effect profiles. This 'comparable to an SSRI' result is the headline of the saffron-depression story.
Small (n=40), short, no placebo arm, and again from the Akhondzadeh/Tehran group. 'As good as fluoxetine' is only as strong as a 40-person pilot allows — and against a low fluoxetine dose.
affron for mood in healthy adults
positive · RCT
Kell et al., 2017, Complementary Therapies in Medicinen=128Industry-fundedThree-arm RCT (n=128): 28 mg/day of the affron extract significantly reduced negative mood and stress/anxiety symptoms vs placebo over 4 weeks (POMS, p<0.001), with a notably large effect size. Extends the signal from clinical depression to subclinical low mood.
Short (4 weeks), subclinical population, and conducted with involvement of the affron producer (Pharmactive). Manufacturer-linked branded-extract trial.
PMS & premenstrual mood
Mechanism
The same serotonergic/mood mechanism that underlies the antidepressant effect is the rationale for premenstrual symptom relief.
One RCT (n=50) found 30 mg/day reduced premenstrual symptom and depression scores over two cycles vs placebo. Consistent with saffron's mood action, but a single small single-center trial.
Preliminary — one small trial. Reasonable to try for premenstrual mood symptoms; not established first-line PMS therapy.
Saffron for premenstrual syndrome
positive · RCT
Agha-Hosseini et al., 2008, BJOGn=5050 women with PMS: saffron 30 mg/day significantly reduced total premenstrual symptom scores and depression ratings vs placebo over two cycles, with good tolerability. A coherent extension of the mood effect into PMS.
Small (n=50), two-cycle duration, and another Iranian single-center trial. Promising for PMS but not independently replicated at scale.
Appetite & snacking control
Mechanism
Proposed serotonergic modulation of mood-driven (emotional) snacking, reducing between-meal eating rather than acting as a metabolic stimulant.
One manufacturer-run RCT (Satiereal, n=60) found reduced snacking and ~1.65 kg weight loss over 8 weeks in mildly overweight women. A modest, single-trial appetite signal — not a weight-loss drug.
One small industry-funded trial in women only. Effect is small and the appetite mechanism is inferred. Don't expect meaningful weight loss on its own.
Satiereal for snacking & satiety
positive · RCT
Gout et al., 2010, Nutrition Researchn=60Industry-funded60 mildly overweight women on Satiereal reduced snacking frequency and reported greater satiety vs placebo, losing ~1.65 kg over 8 weeks (mostly fat) with unrestricted intake. The proposed mechanism is mood/serotonergic modulation of emotional snacking.
Small (n=60), 8 weeks, women only, and run by/for the Satiereal producer (INO'Real). The ~1.65 kg difference is modest and the appetite mechanism is inferred, not proven.
Early macular degeneration (retinal function)
Mechanism
Crocin and crocetin are carotenoids with antioxidant activity in the retina; they are proposed to protect photoreceptor and macular function under oxidative stress.
Two crossover RCTs (n=25 and n=100) of 20 mg/day saffron showed improved retinal flicker sensitivity and a small, statistically significant visual-acuity gain in early/mild AMD. A real but very small effect on surrogate and short-term measures.
Early/mild AMD only, short trials, tiny acuity effect. Not a substitute for AREDS-type formulations or ophthalmologic management, and not shown to prevent AMD progression long-term.
Saffron for early age-related macular degeneration
positive · RCT
Falsini et al., 2010, Investigative Ophthalmology & Visual Sciencen=25Crossover RCT (n=25): 3 months of 20 mg/day saffron improved fERG-measured retinal flicker sensitivity in early AMD, with a small but significant gain in visual acuity. The crocin/crocetin carotenoids are the proposed retinal-protective agents.
Very small (n=25), short crossover, surrogate (electrophysiological) primary endpoint rather than long-term vision outcomes. A promising retinal-function signal, not proof saffron prevents AMD progression.
Saffron for mild/moderate AMD (larger crossover)
mixed · RCT
Broadhead et al., 2019, Graefe's Archive for Clinical and Experimental Ophthalmologyn=100Larger crossover RCT (n=100): 20 mg/day saffron produced a small but statistically significant improvement in visual acuity (~0.7 ETDRS letters) over 3 months vs placebo. Real and consistent direction, but the magnitude is tiny and clinical relevance is debatable.
The effect size is very small (under one letter of acuity), short follow-up, and on top of standard care. A statistically real but clinically marginal vision signal.
4 forms of Saffron compared
Standardized saffron extract (crocin/safranal)
Crocins and safranal are the bioactive markers; standardization to these is the only way to know you're getting real saffron and not adulterant
Best forMood, mild depression, PMSThe generic form. Because saffron is heavily adulterated, an extract standardized to crocin and/or safranal content is strongly preferable to unspecified 'saffron powder.' Depression trials used ~30 mg/day.
stress28–30 mgaffron®
affron (standardized for Lepticrosalides)
Standardized to ≥3.5% Lepticrosalides (crocin/safranal complex); trialed at 28 mg/day
Best forMood, stress, anxiety, sleepThe most-trialed branded mood extract. Kell 2017 used 28 mg/day for low mood; subsequent trials extend to anxiety and sleep. Manufacturer-linked evidence base.
stress28–28 mgSatiereal®
Satiereal (appetite-targeted extract)
Trialed at 176.5 mg/day extract for snacking/satiety
Best forReducing snacking and emotional eatingThe appetite-positioned saffron extract. Gout 2010 used 176.5 mg/day. Single small manufacturer-run trial.
metabolism176–177 mgAffronEYE®
AffronEYE (vision-targeted extract)
Standardized for crocin; vision trials use ~20 mg/day saffron
Best forEarly/mild age-related macular degeneration (retinal function)The eye-health positioning leans on the crocin/crocetin carotenoid antioxidant story. AMD trials used 20 mg/day saffron. Effect on acuity is small.
vision20–20 mg
Are you deficient? Symptoms, risk groups, lab tests
Saffron is a culinary spice and botanical, not a nutrient — there is no dietary requirement and no 'saffron deficiency.' It is supplemented for the pharmacological effects of its carotenoids (crocin, crocetin) and safranal, chiefly on mood.
Side effects and drug interactions
Side effects
Mild GI upset, drowsiness, or headache
Common
At supplemental doses (≤30 mg/day) saffron is generally well tolerated. Occasional nausea, appetite change, drowsiness, or headache are reported, usually mild.
Anxiety or mood changes
Uncommon
Some people report changes in mood or mild anxiety; uncommon at trial doses.
High-dose toxicity
Severe · Toxic effects reported around 5 g; potentially lethal at ~12–20 g
Saffron is toxic at high doses. Doses around 5 g approach toxicity, and ~12–20 g can be lethal. This is far above any supplemental dose but matters because adulteration and self-dosing with bulk spice are real risks.
Drug interactions
Additive effect
SSRIs / SNRIsMAOIsother antidepressantsSaffron has serotonergic activity; combining it with serotonergic antidepressants is theoretically additive and could contribute to excess serotonergic effect.
Don't combine saffron with prescription antidepressants without medical supervision. Despite trials showing it rivals fluoxetine, that means it acts on similar pathways — not that stacking is safe.
Additive effect
antihypertensivesanticoagulants / antiplateletsSaffron may mildly lower blood pressure and has theoretical antiplatelet activity at higher doses.
Use caution if you take blood-pressure or blood-thinning medication; flag concurrent use to your prescriber.
Other critical caveats
- Saffron is one of the world's most expensive and most adulterated spices. Cheap products are routinely cut with safflower, turmeric, marigold, or dyed fibers. Without standardization to crocin/safranal — or a clinically-trialed branded extract (affron, Satiereal, AffronEYE) — you cannot trust the active dose.
- Most of the positive depression evidence comes from a small number of Iranian research groups (notably the Akhondzadeh group) in small, short trials. The effect is consistent and meta-analysis-backed, but large independent replication outside Iran is still limited, and some branded-extract trials are manufacturer-linked.
- Saffron is toxic at high doses (~5 g) and potentially lethal at ~12–20 g — orders of magnitude above the ~30 mg/day used in trials. Stick to supplemental doses; never self-dose with bulk culinary saffron for mood.
- Pregnancy: high-dose saffron is a uterine stimulant and traditional abortifacient. Avoid supplemental saffron in pregnancy.
Frequently asked
Does saffron actually work for depression?
For mild-to-moderate depression, the evidence is genuinely decent. Placebo-controlled RCTs and a meta-analysis show a clear antidepressant effect, and several head-to-head trials found 30 mg/day comparable to low-dose fluoxetine or imipramine. The honest caveats: most of those trials are small, short, and come from a few Iranian research groups, so independent large-scale replication is still limited. It's a reasonable adjunct for mild low mood — not a replacement for treating moderate-to-severe depression.How much saffron should I take?
The depression and PMS trials used about 30 mg/day, usually split into two doses; the branded mood extract affron was trialed at 28 mg/day. For early macular degeneration the eye trials used 20 mg/day. Don't exceed supplemental doses — saffron becomes toxic in the gram range, far above these milligram doses.Why is saffron supplement quality such a big deal?
Because saffron is one of the most expensive and most adulterated spices in the world. Cheap or fake products get cut with safflower, turmeric, or dyed plant fibers, so a capsule labeled 'saffron' may contain very little real saffron. Look for extracts standardized to crocin and/or safranal, or a clinically-studied branded extract like affron, Satiereal, or AffronEYE, so you know you're actually getting the active compounds the trials used.Is saffron safe to take with antidepressants?
Not without medical supervision. Saffron works partly through serotonin — the same pathway as SSRIs — so the very thing that makes it effective also means combining it with prescription antidepressants is theoretically additive. Talk to your prescriber first. Also avoid saffron supplements in pregnancy, since high doses can stimulate the uterus.
References
- 01Examine.com — Saffron
- 02Hausenblas et al., 2013 — Saffron and major depressive disorder meta-analysis (J Integr Med)
- 03Noorbala et al., 2005 — Saffron vs fluoxetine for depression (J Ethnopharmacol)
- 04Falsini et al., 2010 — Saffron for early AMD (Invest Ophthalmol Vis Sci)
- 05NCCIH — Herbs at a Glance
Last reviewed2026-05-24